Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:receptor_tyrosine_kinase
gptkb:drug |
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:FDA
|
| gptkbp:ATCCode |
L01EX19
|
| gptkbp:brand |
gptkb:Ayvakit
|
| gptkbp:CASNumber |
1703793-34-3
|
| gptkbp:chemicalFormula |
C26H27F6N5O3
|
| gptkbp:developer |
gptkb:Blueprint_Medicines
|
| gptkbp:hasSMILES |
CC1=CC2=C(C=C1)N=C(N2)N3CCN(CC3)C(=O)C4=CC=C(C=C4)C5=NC6=C(N5)C=CC(=C6)C(F)(F)F
|
| https://www.w3.org/2000/01/rdf-schema#label |
Avapritinib
|
| gptkbp:KEGGID |
D11260
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
inhibits KIT
inhibits PDGFRA |
| gptkbp:molecularWeight |
560.5 g/mol
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:PubChem_CID |
gptkb:CHEMBL3989989
71681573 DB15174 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
vomiting diarrhea edema fatigue cognitive impairment hair color changes |
| gptkbp:UNII |
6KZ7XAZG0E
|
| gptkbp:usedFor |
gptkb:gastrointestinal_stromal_tumor
gptkb:systemic_mastocytosis |
| gptkbp:bfsParent |
gptkb:CStone_Pharmaceuticals
|
| gptkbp:bfsLayer |
7
|